AR040476A1 - N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) - Google Patents
N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)Info
- Publication number
- AR040476A1 AR040476A1 AR20030102464A ARP030102464A AR040476A1 AR 040476 A1 AR040476 A1 AR 040476A1 AR 20030102464 A AR20030102464 A AR 20030102464A AR P030102464 A ARP030102464 A AR P030102464A AR 040476 A1 AR040476 A1 AR 040476A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkyl group
- alkyl
- fluoro
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- -1 9,10-methanoanthracen-9 (10H) -yl Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000005936 piperidyl group Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- VUCWMAJEUOWLEY-UHFFFAOYSA-N 1-$l^{1}-azanylpiperidine Chemical compound [N]N1CCCCC1 VUCWMAJEUOWLEY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
Abstract
Procesos para preparar dichos compuestos, su uso en el tratamiento de obesidad, trastornos psiquiátricos, trastornos cognitivos, trastornos de la memoria, esquizofrenia, epilepsia y estados relacionados, y trastornos neurológicos tales como demencia, esclerosis múltiple, enfermedad de Parkinson, corea de Huntington y enfermedad de Alzheimer, así como trastornos relacionados con el dolor y composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: R1 representa un grupo alcoxi C1-4 optativamente sustituido por uno o más fluoro o un grupo alquilo C1-4 optativamente sustituido por uno o más fluoro; n representa 0 ó 1; R2 representa un grupo alquilo C1-4 optativamente sustituido por uno o más fluoro o un grupo alcoxi C1-4 optativamente sustituido por uno o más fluoro; m representa 0 ó 1; R3 representa H o un grupo alquilo C1-4; L1 representa una cadena alquileno (CH2)r en la cual representa 2 ó 3 ó L1 representa un grupo ciclohexilo donde los dos nitrógenos que llevan R3 y R4, respectivamente, están unidos al grupo ciclohexilo ya sea a través de las posiciones 1,3 ó 1,4 del grupo ciclohexilo o L1 representa un grupo ciclopentilo donde los dos nitrógenos que llevan R3 y R4, respectivamente, están unidos al grupo ciclopentilo a través de la posición 1,3 del grupo ciclopentilo y además cuando R5 representa 9,10-metanoantracen-9(10H)-ilo el grupo -L1-N(R4)- junto representa un anillo piperidilo que está unido a 12 a través del nitrógeno del piperidinilo y a N-R3 a través de la posición 4 del anillo piperidilo con la condición de que, cuando R5 representa 9,10-metanoantracen-9(10H)-ilo entonces r es solamente 2; R4 representa H o un grupo alquilo C1-4 optativamente sustituido por uno o más de los siguientes: un grupo arilo o un grupo heteroarilo; L2 representa un enlace o una cadena alquileno (CH2)2 en la cual s representa 1, 2, ó 3 donde la cadena alquileno se sustituye optativamente por uno o más de los siguientes: un grupo alquilo C1-4, fenilo o heteroarilo; R5 representa arilo, un grupo heterocíclico o un grupo cicloalquilo C3-8 que está optativamente fusionado a un grupo fenilo o a heteroarilo; así como los isómeros ópticos y racematos de los mismos y las sales aceptables para uso farmacéutico de los mismos; con la primera condición de que cuando n es 0, y m es 1 y R2 es metilo ubicado en la posición 4 del anillo quinolina, y R3 es H y R4 es H y L1 es (CH2)2 o (CH2)3 o 1,4-ciclohexilo; y L2 es un enlace, entonces R5 no es 4-metilquinolin-2-ilo; y con una segunda condición de que cuando n es 0, y m es 0 ó 1 y R2 es un grupo alcoxi C1-3 ubicado en la posición 4 del anillo quinolina, y R3 es H o un grupo alquilo C1-3 y R4 es H o un grupo alquilo C1-3 y L1 es (CH2)3 y L2 es metileno optativamente sustituido por uno o más grupos alquilo C1-3 o fenilo, entonces R5 no es fenilo, tienilo o indolilo optativamente sustituido por uno, dos o tres grupos alquilo C1-4 o halo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040476A1 true AR040476A1 (es) | 2005-04-06 |
Family
ID=20288471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102464A AR040476A1 (es) | 2002-07-08 | 2003-07-08 | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060247439A1 (es) |
| EP (1) | EP1528924A1 (es) |
| JP (1) | JP2006501186A (es) |
| CN (1) | CN1665502A (es) |
| AR (1) | AR040476A1 (es) |
| AU (1) | AU2003281194A1 (es) |
| BR (1) | BR0312312A (es) |
| CA (1) | CA2491835A1 (es) |
| CO (1) | CO5680403A2 (es) |
| IL (1) | IL165841A0 (es) |
| IS (1) | IS7653A (es) |
| MX (1) | MXPA05000336A (es) |
| NO (1) | NO20045528L (es) |
| PL (1) | PL374674A1 (es) |
| RU (1) | RU2004138079A (es) |
| SE (1) | SE0202134D0 (es) |
| TW (1) | TW200412957A (es) |
| WO (1) | WO2004004726A1 (es) |
| ZA (1) | ZA200500030B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1464335A3 (en) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
| CN100451004C (zh) * | 2003-03-31 | 2009-01-14 | 大正制药株式会社 | 嘧啶衍生物 |
| EP1706384A1 (en) * | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| WO2005095357A2 (en) * | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
| WO2006035967A1 (en) * | 2004-09-30 | 2006-04-06 | Taisho Pharmaceutical Co., Ltd. | Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
| CA2589695A1 (en) * | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| US7750034B2 (en) | 2006-01-25 | 2010-07-06 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| CA2664031A1 (en) | 2006-09-28 | 2008-04-03 | F. Hoffmann-La Roche Ag | Quinoline derivatives with 5-ht-binding properties |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| DK3252057T3 (da) | 2009-12-04 | 2024-06-17 | Sunovion Pharmaceuticals Inc | Multicykliske forbindelser og fremgangsmåder til anvendelse deraf |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| PE20130781A1 (es) | 2010-07-06 | 2013-07-20 | Astrazeneca Ab | Agentes terapeuticos 976 |
| JP5728099B2 (ja) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AU2017301767A1 (en) | 2016-07-29 | 2019-02-14 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| CN116283877A (zh) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US11542233B2 (en) * | 2016-12-23 | 2023-01-03 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| CN110678205B (zh) | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| KR20200036008A (ko) | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| JP7453148B2 (ja) | 2018-02-16 | 2024-03-19 | サノビオン ファーマシューティカルズ インク | 塩、結晶形態、およびその製造方法 |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| MX2022012833A (es) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos. |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| US20240217951A1 (en) | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240228469A1 (en) | 2022-09-23 | 2024-07-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240239767A1 (en) | 2022-12-16 | 2024-07-18 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN117486758B (zh) * | 2023-10-30 | 2025-12-26 | 南京正济医药研究有限公司 | 一种(1s,3s)-3-氨基环戊基氨基甲酸叔丁酯的制备方法 |
| WO2025196153A1 (en) | 2024-03-20 | 2025-09-25 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2025196155A1 (en) | 2024-03-20 | 2025-09-25 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| TW202539678A (zh) | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020283A (en) * | 1958-10-20 | 1962-02-06 | Abbott Lab | Bis-lepidines |
| AU7997091A (en) * | 1990-05-30 | 1991-12-31 | American Home Products Corporation | Substituted arylsulfonamides and benzamides |
| EP0912551A1 (en) * | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| BR9909994A (pt) * | 1998-04-29 | 2000-12-26 | Smithkline Beecharm P L C | Quinolinas usadas como inibidores de mrs e bactericidas |
| JP4533534B2 (ja) * | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| WO2001082925A1 (en) * | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonists |
| JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| EP1359915A4 (en) * | 2001-01-26 | 2004-07-21 | Smithkline Beecham | UROTENSIN-II RECEPTOR ANTAGONISTS |
-
2002
- 2002-07-08 SE SE0202134A patent/SE0202134D0/xx unknown
-
2003
- 2003-07-03 TW TW092118207A patent/TW200412957A/zh unknown
- 2003-07-04 CA CA002491835A patent/CA2491835A1/en not_active Abandoned
- 2003-07-04 PL PL03374674A patent/PL374674A1/xx not_active Application Discontinuation
- 2003-07-04 RU RU2004138079/04A patent/RU2004138079A/ru not_active Application Discontinuation
- 2003-07-04 EP EP03740771A patent/EP1528924A1/en not_active Withdrawn
- 2003-07-04 MX MXPA05000336A patent/MXPA05000336A/es not_active Application Discontinuation
- 2003-07-04 JP JP2004518963A patent/JP2006501186A/ja active Pending
- 2003-07-04 BR BR0312312-0A patent/BR0312312A/pt not_active IP Right Cessation
- 2003-07-04 WO PCT/GB2003/002884 patent/WO2004004726A1/en not_active Ceased
- 2003-07-04 AU AU2003281194A patent/AU2003281194A1/en not_active Abandoned
- 2003-07-04 CN CN038160749A patent/CN1665502A/zh active Pending
- 2003-07-04 US US10/520,372 patent/US20060247439A1/en not_active Abandoned
- 2003-07-08 AR AR20030102464A patent/AR040476A1/es unknown
-
2004
- 2004-12-16 IL IL16584104A patent/IL165841A0/xx unknown
- 2004-12-17 NO NO20045528A patent/NO20045528L/no unknown
-
2005
- 2005-01-03 ZA ZA200500030A patent/ZA200500030B/en unknown
- 2005-01-19 IS IS7653A patent/IS7653A/is unknown
- 2005-01-28 CO CO05007427A patent/CO5680403A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1528924A1 (en) | 2005-05-11 |
| MXPA05000336A (es) | 2005-03-31 |
| RU2004138079A (ru) | 2005-08-10 |
| IS7653A (is) | 2005-01-19 |
| SE0202134D0 (sv) | 2002-07-08 |
| CO5680403A2 (es) | 2006-09-29 |
| WO2004004726A1 (en) | 2004-01-15 |
| PL374674A1 (en) | 2005-10-31 |
| JP2006501186A (ja) | 2006-01-12 |
| TW200412957A (en) | 2004-08-01 |
| NO20045528L (no) | 2005-04-04 |
| ZA200500030B (en) | 2005-11-11 |
| BR0312312A (pt) | 2005-04-12 |
| AU2003281194A1 (en) | 2004-01-23 |
| IL165841A0 (en) | 2006-01-15 |
| US20060247439A1 (en) | 2006-11-02 |
| CA2491835A1 (en) | 2004-01-15 |
| CN1665502A (zh) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040476A1 (es) | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) | |
| AR031556A1 (es) | Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| AR038183A1 (es) | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| KR927003052A (ko) | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR043046A1 (es) | Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparacion | |
| AR050435A1 (es) | DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS. | |
| CR9959A (es) | Derivados de pirazol | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| AR060268A1 (es) | Tiazolil - dihidro - indazoles | |
| SE0101579D0 (sv) | New compounds | |
| AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) | |
| CO6341621A2 (es) | Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1 | |
| AR051802A1 (es) | Heterociclos antagonistas de mchr1 | |
| AR044478A1 (es) | Derivados de imidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |